Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Link Between Obesity and Diabetes Found

Published: Monday, November 25, 2013
Last Updated: Monday, November 25, 2013
Bookmark and Share
Targeting a single enzyme that raises both sugar and insulin levels in the obese could prevent and treat diabetes.

A single overactive enzyme worsens the two core defects of diabetes—impaired insulin sensitivity and overproduction of glucose—suggesting that a drug targeting the enzyme could help correct both at once, according to mouse studies done by researchers at Columbia University Medical Center.  The findings were published today in the online edition of Cell Metabolism.

A drug that inhibits the enzyme, MK2, eventually could be added to metformin—the current first-line treatment for type 2 diabetes—to achieve better control over insulin and glucose levels than is possible with either drug alone, said the researchers.

“MK2’s compatibility with metformin makes it a very exciting potential drug target,” said Ira Tabas, MD, PhD, Richard J. Stock Professor and Vice Chair of Research in the Department of Medicine and professor of anatomy & cell biology (in physiology and cellular biophysics), who led the study with Lale Ozcan, PhD, associate research scientist.

“The one clear leader among drugs currently available for type 2 diabetes is metformin, which does a pretty good job of attacking both problems. But because metformin is often not enough, we need drugs that can be added to metformin—or used in patients who cannot tolerate metformin,” Dr. Tabas said. “If you take an obese, diabetic mouse and give it metformin, you get a partial improvement. If you give it an MK2-inhibitor, you also get a partial improvement. However, if you give both, the benefit is additive, which is consistent with our data that metformin and MK2 work through different biochemical pathways.”

The researchers’ earlier findings, on MK2’s effects on glucose, were published last year in the same journal.

Though both papers report the biochemical details of how MK2 works in mice, Drs. Tabas and Ozcan, working with surgeons Marc Bessler, MD, and Beth Schrope, MD, PhD, surgeons from NewYork-Presbyterian Hospital/Columbia University medical Center, also have recent unpublished data suggesting that MK2 is overactive in obese people, including those with pre-diabetes, but not in lean people. Moreover, the MK2 pathway is active in human liver cells, and, according to a large human genetic study called DIAGRAM, a key component of the pathway that activates MK2 is associated with diabetes.

About 25.8 million people in the U.S. and 347 million people worldwide have diabetes (mostly type 2). According to the Centers for Disease Control and Prevention, each year, about 6 percent of people with pre-diabetes develop type 2 diabetes; unless they make lifestyle changes, about 15 to 30 percent will develop diabetes within five years. “In addition to improving insulin sensitivity and glucose levels, our data suggest to us that a drug that inhibits MK2 could prevent the progression of pre-diabetes to full diabetes,” Dr. Tabas said.

Such a drug could protect the cells that produce insulin. “As the disease progresses, the insulin-producing cells have to put out more and more insulin to deal with the ever-increasing amounts of glucose in the bloodstream. Eventually, they burn out and the patient must use insulin,” Dr. Tabas said. “If we can protect the pancreas’s beta cells from the stress of dealing with high glucose, we may be able to prevent or delay progression to full diabetes.”

Drs. Tabas and Ozcan are planning to test this hypothesis with pre-diabetic mice.

Inhibiting MK2 also reduces cholesterol

Unpublished data from Drs. Tabas and Ozcan also suggest that MK2 inhibitors may not carry the cardiovascular risks associated with several newer diabetes drugs. Because of these risks, the FDA will not approve a new diabetes drug unless it has been found to be safe in large clinical trials designed to detect cardiovascular risk.

The Columbia researchers’ mouse studies show that MK2 inhibition reduces cholesterol, and other researchers have found that MK2 deficiency in mice protects against atherosclerosis. “A drug that inhibits MK2 may not just be heart-safe, but may actually be cardio-protective,” Dr. Tabas said.

He and Dr. Ozcan have created a company to develop compounds able to inhibit MK2.

“As with all drug development, it’s a long shot, but we think MK2 is less of a long shot than most.”

Drs. Tabas’ and Ozcan’s paper is titled, “Activation of Calcium/Calmodulin-Dependent Protein Kinase II in Obesity Mediates Suppression of Hepatic Insulin Signaling.”

This work was supported by NIH grants HL087123 and HL075662; American Heart Association Scientist Development Grant 11SDG5300022; NYONRC Pilot and Feasibility Grant DK26687; FAPESP/BEPE 2012/21290-4; German Center for Cardiovascular Research; the German Ministry of Education and Research; Deutsche Forschungsgemeinschaft BA 2258/2-1; European Commission FP7-Health-2010; and MEDIA-261409.  The basic science at the foundation of this work is part of a large NIH-sponsored program undertaken with two other CUMC professors, Domenico Accili, MD, and Alan Tall, MD, who have provided valuable guidance throughout these studies.

Drs. Ozcan and Tabas are among the co-founders of Tabomedex Biosciences LLC, which is developing inhibitors of the pathway described above for treatment of type 2 diabetes. The authors declare no additional financial or other conflicts of interest.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Is There a Role for Vitamins in Cancer Prevention?
According to recent national surveys, approximately 40 percent of U.S. adults take multivitamins/multiminerals.
Monday, August 12, 2013
Study Reveals Genes That Drive Brain Cancer
About 15 percent of glioblastoma patients could receive personalized treatment with drugs currently used in other cancers.
Tuesday, August 06, 2013
Key Molecular Pathways Leading to Alzheimer’s Identified
Research approach highlights potential therapeutic targets.
Thursday, July 25, 2013
New Genetic Cause of Pulmonary Hypertension Identified
Study finds druggable target for rare fatal lung disease.
Thursday, July 25, 2013
Mutation Linked to Congenital Urinary Tract Defects
Findings point to new diagnostic category.
Thursday, July 18, 2013
Mouse Study Suggests Lead May Trigger Schizophrenia
Behavioral and MRI study in mice points to a synergistic relationship between lead exposure and schizophrenia gene.
Monday, June 10, 2013
Many Birth Defects in Heart Caused by Spontaneous Mutations
A study has found that at least 10 percent of cases stem from genetic mutations that occur spontaneously early in development.
Thursday, May 30, 2013
Common Childhood Asthma Not Rooted in Allergens, Inflammation
Discovery of origins of a unique form of asthma may lead to a precision medicine approach to treatment.
Friday, May 24, 2013
Looking for the Telltale Gene
A new genetic test allows parents to peer into their unborn children's medical future.
Friday, May 24, 2013
Hundreds of Alterations and Potential Drug Targets to Starve Tumors Identified
A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.
Monday, April 22, 2013
New Gene Associated with Almost Doubled Alzheimer’s Risk in African-Americans
ABCA7, a minor gene variant in whites, is major player in African-Americans.
Wednesday, April 10, 2013
Schizophrenia Gene Networks Found, and a Link to Autism
Although schizophrenia is highly genetic in origin, the genes involved in the disorder have been difficult to identify.
Thursday, November 15, 2012
New de novo Genetic Mutations in Schizophrenia Identified
Columbia University Medical Center (CUMC) researchers have identified dozens of new spontaneous genetic mutations that play a significant role in the development of schizophrenia, adding to the growing list of genetic variants that can contribute to the disease.
Thursday, October 04, 2012
New de novo Genetic Mutations in Schizophrenia Identified
Columbia University Medical Center (CUMC) researchers have identified dozens of new spontaneous genetic mutations that play a significant role in the development of schizophrenia, adding to the growing list of genetic variants that can contribute to the disease.
Thursday, October 04, 2012
Tom Maniatis: A Deep Sense that Science Must Be Shared
History books are filled with the technical advances that made genetic engineering possible, from the discovery of enzymes that cut and paste DNA to the development of techniques for reading the sequence of genes.
Tuesday, September 11, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!